 |
 |

Cryoprecipitate as a Reliable Source of Fibrinogen Replacement
Paul M. Ness, MD;
Herbert A. Perkins, MD
JAMA. 1979;241(16):1690-1691.
Abstract
The recent withdrawal of commercial fibrinogen from the market makes alternate sources most important. Although it has been previously reported that single-donor cryoprecipitate contains appreciable amounts of fibrinogen, most clinicians need to be reminded of the reliability of cryoprecipitate for replacement of both fibrinogen and factor VIII. We assayed fibrinogen from 88 bags of cryoprecipitate prepared by five different blood banks in California and Oregon; we found that the average bag of cryoprecipitate contains at least 250 mg of fibrinogen depending on the volume of plasma processed. Cryoprecipitate was found to be a poor source of factors II, V, IX, X, XI, and XII.
(JAMA 241:1690-1691, 1979)
Author Affiliations
From the Irwin Memorial Blood Bank of the San Francisco Medical Society, San Francisco.
Footnotes
Reprint requests to Irwin Memorial Blood Bank, 270 Masonic Ave, San Francisco, CA 94118 (Dr Ness).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Fibrin Sealant as a Hemostatic Agent in Vascular Surgery
Jackson
PERSPECT VASC SURG ENDOVASC THER 2000;13:85-94.
ABSTRACT
Efficacy of a Dry Fibrin Sealant Dressing for Hemorrhage Control After Ballistic Injury
Holcomb et al.
Arch Surg 1998;133:32-35.
ABSTRACT
| FULL TEXT
CryoSealTM System, a New Device for Generating Cryoprecipitate from Plasma
Gosselin et al.
Clin. Chem. 1997;43:1782-1783.
FULL TEXT
Practice Parameter for the Use of Fresh-Frozen Plasma, Cryoprecipitate, and Platelets
Fresh-Frozen Plasma, Cryoprecipitate, and Platelet et al.
JAMA 1994;271:777-781.
ABSTRACT
Bleeding during Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management
Sane et al.
ANN INTERN MED 1989;111:1010-1022.
ABSTRACT
Prophylactic Cryoprecipitate in Congenital Afibrinogenemia
Rodriguez et al.
CLIN PEDIATR 1988;27:543-545.
ABSTRACT
|